AcclaimIP-ad

Match Document Document Title
US20130183308 THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS  
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
US20130177561 THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS  
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
US20130129830 Polymer Protein Microparticles  
Microparticles containing a core of therapeutic protein and a cortex of a biocompatible and biodegradable polymer, and methods of making and using the microparticles are provided. The extended...
US20100015144 Methods for dosing an activin-actriia antagonist and monitoring of treated patients  
In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa anatagonist. In...
US20100008918 Methods for dosing an actriib antagonist and monitoring of treated patients  
In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain...
US20170051039 COMPOSITIONS COMPRISING A P75 TUMOR NECROSIS FACTOR RECEPTOR/IG FUSION PROTEIN  
The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods...
US20170042967 TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS  
The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
US20170022271 MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS  
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described....
US20170015747 CD86 ANTAGONIST MULTI-TARGET BINDING PROTEINS  
This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an...
US20170008960 TCR Complex Immunotherapeutics  
Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCRα, TCRβ, or CD3ε, along with compositions and methods of use thereof are provided.
US20160297854 COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES  
The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid...
US20160220540 COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES  
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example,...
US20160194395 Fusion proteins and their related methods  
The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex...
US20160176926 PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1  
The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4...
US20160144025 METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES  
The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof...
US20160009805 ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF  
The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
US20150299329 ANTIGEN PRESENTING CELL TARGETED VACCINES  
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to...
US20150252097 TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR  
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins...
US20150216795 ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT  
Article of manufacture comprising a packaging material, a polypeptide of SEQ ID NO:1, aflibercept or ziv-aflibercept or a biosimilar thereof, and a label comprising a printed statement which...
US20150056199 TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF  
In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize...
US20150044207 Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia  
The Invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a...
US20150017163 Methods for Treating or Preventing Ophthalmological Conditions  
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt...
US20140363432 VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF  
The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF...
US20140335086 MODIFIED HEAT SHOCK PROTEIN-ANTIGENIC PEPTIDE COMPLEX  
The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic...
US20140227269 THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS  
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
US20140186350 COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES  
The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid...
US20140079699 METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R)  
Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not...
US20140065097 Immunotherapy  
The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased...
US20130344066 METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS  
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA...
US20130309230 Modified Antibody Compositions, Methods of Making and Using Thereof  
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a...
US20130280251 Stabilized Angiopoietin-2 Antibodies And Uses Thereof  
Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are...
US20130195860 Antibody targeting through a modular recognition domain  
The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more...
US20130078245 ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3  
The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP),...
US20120251537 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS  
PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced...
US20120237514 VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF  
The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF...
US20120230992 VEGF-RELATED PROTEIN  
A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third...
US20120189626 TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS  
The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
US20120114556 IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS  
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
US20120064075 CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE  
The present invention relates to novel proteins and methods of using chimeric Factor VIIa polypeptides.
US20120052067 ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS  
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly...
US20120034159 ANTIBODIES THAT BIND BOTH BCMA AND TACI  
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic...
US20120014952 COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS  
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that...
US20110311534 WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS  
The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc...
US20110250198 ActRIIB FUSION POLYPEPTIDES AND USES THEREFOR  
Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing,...
US20110206668 METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY  
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The...
US20110070233 ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF  
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for...
US20100266593 WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS  
The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc...
US20100189651 MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF  
The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a...
US20100150925 TREATMENT OF B-CELL CANCERS WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES  
Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody...
US20100061985 ANTAGONISTS OF TWEAK AND OF TWEAK RECEPTOR AND THEIR USE TO TREAT IMMUNOLOGICAL DISORDERS  
The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.